Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]

DRUG2 trials

Sponsors

Instituto de Investigación Marqués de Valdecilla, Maimónides Biomedical Research Institute of Córdoba

Conditions

AtherosclerosisRheumatoid ArthritisSARSSARS-CoV 2

Phase 2

Clinical Trial of Sarilumab in Adults With COVID-19

CompletedNCT04357860

Maimónides Biomedical Research Institute of CórdobaSARS, SARS-CoV 2

Start: 2020-04-28End: 2021-04-06Updated: 2021-07-07

Phase 4

Effect of Sarilumab on Atherosclerotic Disease Assessed by PET/CET in Patients With RA (SARIPET)

Instituto de Investigación Marqués de ValdecillaAtherosclerosis, Rheumatoid Arthritis

Start: 2020-04-30End: 2021-04-30Target: 20Updated: 2020-04-27

Related Papers

Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis.

2022-12-0128 citations

Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical Trial.

2021-12-1327 citations

Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial

BMJ Open2020-11-0116 citations